Skip to main content

Table 2 Clinical characteristics of patients with moderate COVID-19 on admission

From: Early changes in laboratory tests predict liver function damage in patients with moderate coronavirus disease 2019: a retrospective multicenter study

Characteristics

Training set (n = 70)

Validation set (n = 31)

All patients (n = 70)

Liver function damage group (n = 45)

Normal liver function group (n = 25)

All patients (n = 31)

Liver function damage group (n = 21)

Normal liver function group (n = 10)

Sex n (%)

      

Male

34 (48.6)

22 (48.9)

12 (48.0)

14 (45.2)

8 (38.1)

6 (60.0)

Female

36 (51.4)

23 (51.1)

13 (52.0)

17 (54.8)

13 (61.9)

4 (40.0)

Age (years) \(\overline{x }\pm s\)/M (IQR)

52.81 ± 15.92

54.11 ± 15.77

50.48 ± 16.24

52.06 ± 18.52

56.14 ± 18.41

43.50 ± 16.44

Any comorbidities n (%)

Cardiovascular disease

18 (25.7)

14 (31.1)

4 (16.0)

5 (16.1)

4 (19.1)

1 (10.0)

Endocrine system disease

8 (11.4)

4 (8.9)

4 (16.0)

4 (12.9)

4 (19.1)

-

Others

11 (15.7)

9 (20.0)

2 (8.0)

5 (16.1)

4 (19.1)

1 (10.0)

Chief complaint n (%)

Cough

34 (48.6)

27 (60.0)*

7 (28.0)

20 (64.5)

14 (66.7)

6 (60.0)

Fever

21 (30.0)

15 (33.3)

6 (24.0)

11 (35.5)

10 (47.6)

1 (10.0)

Fatigue

9 (12.7)

6 (13.3)

3 (12.0)

7 (22.6)

4 (19.1)

3 (30.0)

Others

11 (15.7)

8 (17.8)

3 (12.0)

10 (32.3)

7 (33.3)

3 (30.0)

Drug use n (%)

Traditional Chinese medicine

59 (84.3)

39 (86.7)

20 (80.0)

23 (74.2)

17 (81.0)

6 (60.0)

Antiviral drugs

54 (77.1)

32 (71.1)

22 (88.0)

19 (61.3)

13 (61.9)

6 (60.0)

Anti-inflammatory drugs

12 (17.1)

8 (17.8)

4 (16.0)

2 (6.5)

2 (9.5)

Others

16 (22.9)

12 (26.7)

4 (16.0)

1 (3.2)

1 (10.0)

Length of hospitalization (days) \(\overline{x }\pm s\)/M (IQR)

19.69 ± 6.90

19.42 ± 7.60

20.16 ± 5.54

20.00 (16.00–24.00)

20.00 (17.00–24.00)

16.50 (11.75–21.25)

  1. COVID-19: coronavirus disease 2019. \(\overline{x }\): Average. s: Standard deviation. M (IQR): Median (Quartile)
  2. *Significant difference between the liver function damage group and the normal liver function group, P < 0.05